Holen Sie sich die Stockscreener-App
32.37
4.14%
1.30
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt ALKS?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$31.07
Offen:
$31.03
24-Stunden-Volumen:
705.67K
Relative Volume:
0.34
Marktkapitalisierung:
$5.34B
Einnahmen:
$1.51B
Nettoeinkommen (Verlust:
$333.35M
KGV:
16.60
EPS:
1.95
Netto-Cashflow:
$315.22M
1W Leistung:
+4.98%
1M Leistung:
+4.40%
6M Leistung:
+6.57%
1J Leistung:
+10.46%
1-Tages-Spanne:
$30.66
$32.42
1-Wochen-Bereich:
$29.70
$36.32
52-Wochen-Spanne:
$25.16
$36.45
Alkermes Plc Stock (ALKS) Company Profile
Firmenname
Alkermes Plc
Sektor
Telefon
00-353-1-772-8000
Adresse
CONNAUGHT HOUSE, DUBLIN 4
Vergleichen Sie ALKS mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ALKS
Alkermes Plc
|
32.36 | 5.13B | 1.51B | 333.35M | 315.22M | 1.95 |
|
ZTS
Zoetis Inc
|
120.35 | 53.10B | 9.40B | 2.65B | 2.22B | 5.935 |
|
TAK
Takeda Pharmaceutical Co Adr
|
13.63 | 42.93B | 29.63B | 260.53M | 5.51B | 0.0788 |
|
HLN
Haleon Plc Adr
|
9.40 | 41.46B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
24.25 | 28.22B | 16.70B | -157.13M | 1.19B | -0.1446 |
|
UTHR
United Therapeutics Corp
|
451.87 | 19.27B | 3.08B | 1.24B | 1.07B | 25.61 |
Alkermes Plc Stock (ALKS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-09-26 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2025-09-03 | Eingeleitet | Wells Fargo | Overweight |
| 2025-07-15 | Eingeleitet | Goldman | Buy |
| 2025-06-17 | Hochstufung | UBS | Neutral → Buy |
| 2025-05-28 | Eingeleitet | Needham | Buy |
| 2025-03-13 | Eingeleitet | RBC Capital Mkts | Sector Perform |
| 2025-03-04 | Hochstufung | UBS | Sell → Neutral |
| 2025-02-11 | Eingeleitet | Deutsche Bank | Buy |
| 2024-11-05 | Hochstufung | Stifel | Hold → Buy |
| 2024-06-17 | Eingeleitet | TD Cowen | Buy |
| 2024-03-19 | Eingeleitet | Robert W. Baird | Outperform |
| 2024-02-20 | Herabstufung | UBS | Neutral → Sell |
| 2023-11-20 | Fortgesetzt | JP Morgan | Neutral |
| 2023-10-24 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2023-10-17 | Eingeleitet | UBS | Neutral |
| 2022-11-03 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2022-10-14 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2022-08-16 | Eingeleitet | Piper Sandler | Neutral |
| 2022-04-22 | Fortgesetzt | Goldman | Buy |
| 2022-04-20 | Eingeleitet | Goldman | Buy |
| 2022-01-27 | Hochstufung | Cantor Fitzgerald | Hold → Overweight |
| 2021-12-01 | Eingeleitet | Citigroup | Neutral |
| 2021-10-07 | Hochstufung | Jefferies | Hold → Buy |
| 2021-09-02 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2020-10-15 | Hochstufung | Mizuho | Neutral → Buy |
| 2020-07-30 | Herabstufung | Goldman | Neutral → Sell |
| 2020-02-14 | Herabstufung | BofA/Merrill | Buy → Neutral |
| 2020-02-14 | Bestätigt | H.C. Wainwright | Neutral |
| 2020-02-14 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2020-02-06 | Eingeleitet | Mizuho | Neutral |
| 2020-01-31 | Hochstufung | Wolfe Research | Underperform → Peer Perform |
| 2019-09-05 | Hochstufung | Morgan Stanley | Underweight → Equal-Weight |
| 2019-07-15 | Hochstufung | Goldman | Sell → Neutral |
| 2019-05-31 | Eingeleitet | H.C. Wainwright | Neutral |
| 2019-05-01 | Herabstufung | Citigroup | Buy → Neutral |
| 2018-12-19 | Herabstufung | Goldman | Neutral → Sell |
| 2018-12-14 | Eingeleitet | Wolfe Research | Underperform |
| 2018-12-13 | Herabstufung | Credit Suisse | Outperform → Underperform |
| 2018-11-05 | Eingeleitet | Piper Jaffray | Neutral |
| 2018-08-07 | Eingeleitet | Stifel | Hold |
| 2018-06-21 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2018-06-06 | Eingeleitet | B. Riley FBR, Inc. | Buy |
| 2018-05-16 | Hochstufung | Citigroup | Neutral → Buy |
| 2018-05-11 | Eingeleitet | BofA/Merrill | Buy |
Alle ansehen
Alkermes Plc Aktie (ALKS) Neueste Nachrichten
Is Alkermes (ALKS) Stock Outpacing Its Medical Peers This Year? - Yahoo! Finance Canada
Can Alkermes plc stock maintain growth trajectory2025 Technical Patterns & Free Fast Entry Momentum Trade Alerts - newser.com
What data driven models say about Alkermes plc’s futureBuy Signal & Weekly Setup with ROI Potential - newser.com
Exit strategy if you’re trapped in Alkermes plcGold Moves & Free Safe Entry Trade Signal Reports - newser.com
How Alkermes plc (8AK) stock valuation compares with sectorEarnings Performance Report & Growth Focused Stock Reports - newser.com
How high can Alkermes plc stock goStop Loss & Technical Pattern Based Signals - newser.com
Will Alkermes plc stock rally after Fed decisionsWeekly Profit Report & Daily Chart Pattern Signals - newser.com
Relative strength of Alkermes plc in sector analysisMarket Sentiment Summary & Weekly Momentum Stock Picks - newser.com
What to do if you’re stuck in Alkermes plc2025 Volatility Report & Technical Entry and Exit Tips - newser.com
Applying Elliott Wave Theory to Alkermes plcPortfolio Gains Report & Fast Gain Stock Trading Tips - newser.com
Comparing Alkermes plc in custom built stock radarsWeekly Volume Report & Weekly Breakout Opportunity Watchlist - newser.com
Why Alkermes plc stock is seen as undervaluedPortfolio Gains Report & Stock Timing and Entry Methods - newser.com
Can Alkermes plc stock beat analyst upgrades2025 EndofYear Setup & Smart Allocation Stock Reports - fcp.pa.gov.br
Drug company's St. Louis-area operations to be 'under review' in $2.1B planned sale - The Business Journals
Will Alkermes plc (8AK) stock gain from lower interest rates2025 Bull vs Bear & Long-Term Growth Portfolio Plans - fcp.pa.gov.br
RBC says Centessa data highlights ‘impressive profile’ of Alkermes’ alixorexton - TipRanks
Alkermes (ALKS) Positioned Strongly in Sleep Disorder Market - GuruFocus
Alkermes stock poised for gains as RBC sees rival data removing overhang - Investing.com Nigeria
Centessa narcolepsy data not superior to Alkermes, says Stifel - TipRanks
What recovery options are there for Alkermes plc2025 Price Action Summary & Weekly Market Pulse Alerts - newser.com
Alkermes (ALKS) Shares Rise in Morning Trading - GuruFocus
Alkermes (ALKS) Poised for Gains on Narcolepsy Study News - GuruFocus
Centessa touts OX2R agonist data in broad narcolepsy trial - BioWorld MedTech
FORM 8.1(a) & (b) (Opening Position Disclosure) - PR Newswire
What moving averages say about Alkermes plcJuly 2025 Reactions & Verified Swing Trading Watchlist - newser.com
Why Alkermes plc stock appeals to analystsJuly 2025 PostEarnings & AI Based Buy/Sell Signal Reports - newser.com
Analysts Just Made An Incredible Upgrade To Their Alkermes plc (NASDAQ:ALKS) Forecasts - Yahoo Finance
How resilient is Alkermes plc stock in market downturns2025 Trading Volume Trends & Weekly High Return Stock Opportunities - newser.com
Real time social sentiment graph for Alkermes plcJuly 2025 Review & High Conviction Investment Ideas - newser.com
Avadel Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Corporate Update - The Globe and Mail
Order flow analysis tools used on Alkermes plcMarket Performance Recap & Stock Portfolio Risk Management - newser.com
Is Alkermes plc (8AK) stock a safe buy pre earningsPortfolio Risk Summary & Reliable Entry Point Trade Alerts - newser.com
Price momentum metrics for Alkermes plc explained2025 Volume Leaders & Safe Capital Growth Trade Ideas - newser.com
Is Alkermes plc forming a bottoming baseEarnings Overview Summary & Short-Term Swing Trade Alerts - newser.com
Craig Hopkinson Sells 9,000 Shares of Alkermes (NASDAQ:ALKS) Stock - MarketBeat
How Alkermes Plc (ALKS) Affects Rotational Strategy Timing - news.stocktradersdaily.com
Hussman Strategic Advisors Inc. Acquires New Holdings in Alkermes plc $ALKS - MarketBeat
Can Alkermes plc stock deliver consistent earnings growthJuly 2025 Highlights & Verified Short-Term Plans - newser.com
Risk vs reward if holding onto Alkermes plcJuly 2025 PostEarnings & AI Driven Stock Price Forecasts - newser.com
Is Alkermes plc (8AK) stock at risk of policy regulationGold Moves & Weekly Chart Analysis and Guides - newser.com
Finanzdaten der Alkermes Plc-Aktie (ALKS)
Umsatz
Nettogewinn
Free Cashflow
ENV
Alkermes Plc-Aktie (ALKS) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Hopkinson Craig C. | EVP R&D, Chief Medical Officer |
Nov 03 '25 |
Sale |
30.38 |
9,000 |
273,442 |
69,740 |
7.52%
0.59%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):